What's Happening?
Altesa BioSciences has presented new data demonstrating that its antiviral drug, vapendavir, is effective against all three species of rhinovirus, including Rhinovirus C (RV-C). This finding challenges previous assumptions about the treatability of RV-C with
capsid inhibitors. The data was presented at the 2026 International Conference on Antiviral Research. Vapendavir, a rhinovirus capsid inhibitor, has shown clinically meaningful activity in both in vitro and in vivo studies. The drug is currently being tested in a Phase 2b clinical trial, known as the CARDINAL study, involving COPD patients with rhinovirus infections.
Why It's Important?
Rhinovirus is a major cause of acute exacerbations in COPD patients, and current treatments focus on managing symptoms rather than addressing the underlying viral cause. Vapendavir's ability to target rhinovirus directly could transform the treatment landscape for respiratory infections, offering a preemptive option for vulnerable patients. This development could lead to improved patient outcomes, reduced healthcare costs, and a shift in how respiratory infections are managed in high-risk populations.
What's Next?
The CARDINAL Phase 2b study will continue to evaluate vapendavir's efficacy in COPD patients, with results expected to inform future regulatory submissions. If successful, vapendavir could become a new standard of care for managing rhinovirus infections in COPD patients. Altesa BioSciences plans to explore broader applications of vapendavir in other respiratory conditions, potentially expanding its market reach and impact on public health.
